Anti-Ceacam1 Monoclonal Antibody Cm-24
Colorectal Adenocarcinoma
Explore 67 assets in Colorectal Adenocarcinoma →Floatz Rating
CC46/100
Confidence
Indicative
Sponsor
Famewave Ltd.
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04731467CT.gov A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Anti-Ceacam1 Monoclonal Antibody Cm-24 (this asset) | Famewave Ltd. | P1/2 | CC · 46 |
| Trifluridine | Centre Hospitalier Universitaire Dijon | P3 | BB |
| Regorafenib | City of Hope Medical Center | P2 | BB |
| Botensilimab | City of Hope Medical Center | P2 | BB |
| Balstilimab | City of Hope Medical Center | P2 | BB |
| Tipiracil | Academic and Community Cancer Research United | P2 | BB |
| Fluorouracilum | Centre Hospitalier Universitaire Dijon | P3 | BB |
| Cetuximab | Bayer | P2 | BB |
| Nivolumab | University Hospital, Akershus | P2 | B |
+42 more in the Colorectal Adenocarcinoma cohort
Other indications for Anti-Ceacam1 Monoclonal Antibody Cm-24
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Thyroid Gland Papillary Carcinoma | — | P1/2 | CCC · 52 |
| Non-Small Cell Lung Carcinoma | — | P1/2 | CC · 47 |
| Melanoma | — | P1/2 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Anti-Ceacam1 Monoclonal Antibody Cm-24 in Colorectal Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/anti-ceacam1-monoclonal-antibody-cm-24-colorectal-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →